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a b s t r a c t
Drug testing with traditional behavioral assays constitutes a major bottleneck in the development of
novel therapies. PsychoGenics developed three comprehensive highthroughtput systems, SmartCubes,
NeuroCubes and PhenoCubes systems, to increase the efﬁciency of the drug screening and phenotyping
in rodents. These three systems capture different domains of behavior, namely, cognitive, motor,
circadian, social, anxiety-like, gait and others, using custom-built computer vision software and machine
learning algorithms for analysis. This review exempliﬁes the use of the three systems and explains how
they can advance drug screening with their applications to phenotyping of disease models, drug
screening, selection of lead candidates, behavior-driven lead optimization, and drug repurposing.
& 2015 Elsevier B.V. All rights reserved.
1. Introduction
Neuropsychiatric, developmental and neurodegenerative dis-
orders are complex and involve multiple neuronal circuits. Target-
based approaches have, for the most part, failed to deliver mean-
ingful treatments, whereas phenotypic screening is proved more
successful. In the period between 1999 and 2008, 75 ﬁrst-in-class
drugs with novel mechanism of action were approved. Of the ﬁrst-
in-class drugs, 28 were discovered using phenotypic screening vs.
17 using target-based approaches. Speciﬁcally in CNS, 7 of the 8
ﬁrst-in-class drugs approved were discovered using phenotypic
screening (Swinney and Anthony, 2011).
It is not surprising, therefore that many of the most efﬁcacious
drugs, especially in psychiatry, have multiple targets and were discov-
ered by serendipity (observing how an animal's behavior was altered
in response to the drug). Since the goal of any neuropsychiatric drug is
to impact behavior, PsychoGenics has industrialized “serendipity”with
its behavior-based technologies.
PsychoGenics' proprietary behavior-based technologies, also known
as the SmartCubes, NeuroCubes and PhenoCubes systems, combine
behavioral neurobiology insight integrated with advances in robotics
and computer vision (video capture and analysis) and the power of
bioinformatics to process and analyze massive temporal and vectorial
datasets using probabilistic causal inference algorithms (Fig. 1). The
technologies offer numerous distinct advantages over current beha-
vioral assessment including the following:
High throughput – can screen tens of thousands of compounds
for CNS activity and identify those with a behavioral proﬁle that
reverses a disease model phenotype or is reminiscent of drugs
that treat a speciﬁc neuropsychiatric disorder;
High content – thousands of features are collected and proprie-
tary bioinformatics algorithms are employed to detect subtle
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phenotypic differences associated with a disease model or drug
effect.
Unbiased – Computer vision algorithms and bioinformatics
eliminate human intervention and subjectivity.
PsychoGenics uses its platforms at all stages of drug discovery
as described below, to identify novel treatments addressing major
unmet neuropsychiatric disorders that are unlikely to be found by
other means. Platform applications include:
 Screening representative compounds from diverse CNS libraries.
This approach is agnostic to compound mechanism of action;
 Re-purposing compounds that are discontinued (for reasons
other than safety) or currently being developed for other non-
CNS indications;
 Screening target-focused compounds to determine the thera-
peutic utility of a target or identifying a preferred chemotype;
 Assessing compound combinations (i.e. determining the efﬁcacy of
a combination of novel compounds or a novel compound com-
bined with an existing marketed drug);
 Lead optimization.
Using this approach, PsychoGenics has identiﬁed several drug
candidates at various stages of clinical and preclinical develop-
ment on its own and in partnership with other companies.
2. The SmartCubes system
The SmartCubes system is a high-throughput automated beha-
vioral platform that presents a sequence of challenges to a mouse
through its customized hardware, extracts more than 2000 features
per session, and, using proprietary bioinformatics, and detects the
potential therapeutic efﬁcacy of compounds.
SmartCubes employs computer vision andmechanical actuators to
detect spontaneous and evoked behavior eliciting responses through
anxiogenic and startling stimuli. Behavioral readouts include locomo-
tion, trajectory complexity, body posture and shape, simple behaviors
and behavioral sequences (Brunner et al., 2002; Houghten et al., 2008;
Roberds et al., 2011). Supervised machine learning algorithms are used
to analyze the collected features. Although approximately ½ million
datapoints are collected per mouse per session, behavioral deﬁnitions,
machine learning techniques and smart voting under uncertainty, are
used to reduce this dataset to2000 target features.
PsychoGenics' proprietary supervised machine learning metho-
dology, derived from minimization of Bayesian misclassiﬁcation
probability, similar in spirit to Support Vector Machines, is used to
train a classiﬁcation algorithm that reliably maps behavioral fea-
tures for each drug to its corresponding biological response “label”
(e.g. CNS Indication or Mechanism of Action). The original feature
space undergoes non-linear transformation using a proprietary
semi-blind source separation variant of Independent Component
Analysis to minimize “overcounting”, during calculation of the con-
tribution of overrepresented original features, and reduce the effetive
(new) feature dimensionality. The output of the resulting classiﬁcation
algorithm is a probability distribution over the chosen set of labels
which, in addition to a speciﬁc biological response, predicts quantities
such as “unknown activity” (difference from vehicle not attributable
to any speciﬁc feature patterns in the training set) as well as “total
activity” of the drug (Fig. 2).
Two major types of analyses are routinely conducted: Class and
Subclass. For Class and Subclass analyses, a reference data set has been
built from hundreds of drug doses grouped in multiple drug classes
plus a vehicle class. Dose responses for the reference drugs were
constructed using multiple doses targeting both efﬁcacious doses as
well as doses that exhibit side effect proﬁles in mice. The Class analysis
uses labels and corresponding drugs that are currently in the market
or have been clinically validated for a speciﬁc therapeutic indication.
The Subclass analysis uses labels and a larger set of compounds
selected from both marketed drugs and compounds validated for
speciﬁc therapeutic uses. The reference databases are continually
expanding with the addition of novel therapeutics and new proprie-
tary databases are currently in development.
Novel compounds can be tested in SmartCubes system and the
results can then be compared to the signatures of reference com-
pounds in PsychoGenics' database. Multiple analyses of the data are
performed to quantitatively produce independent predictions of drug
class, and drug subclass. The system, therefore, can, in an unbiased
way classify compounds according to the therapeutic potential by
comparing their complex behavioral proﬁles with those from a pro-
prietary reference database.
The results for the class and subclass analyses are presented as
standardized bar charts with percentages that sum to 100 for each
dose. The results of the classiﬁcation at the drug level are presented
as individual similarities. An example of the output of a typical
classiﬁcation is shown in Fig. 2A.
Fig. 2B shows a different use of the system, as a full proﬁle appears
when a large dose response is run, in this case for diazepam. The drug
goes from inactive at .25 mg/kg to anxiolytic between 1.0 and 2.0 and
Fig. 1. SmartCubes combines behavioral neurobiology insight integrated with advances in robotics and computer vision (video capture and analysis) and the power of
bioinformatics to process and analyze massive temporal and vectorial datasets using probability causal inference algorithms. SmartCubes is a platform that provides a
sequence of challenges to a mouse, extracts more than 2000 features during a session and using proprietary bioinformatics detects the potential of compounds to treat
psychiatric disorders in an unbiased way by comparing their complex behavioral proﬁles with those from a proprietary reference database.
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sedative at higher doses. In this way, therefore, a therapeutic window
and complete proﬁle can be established for any drug. An interesting
characteristic of the total pharmacological activity represented by the
height of the colored bar is that it captures all beneﬁcial, neutral,
detrimental and unknown effects of the drug, so it continues to grow
as the dose increases, but the color proﬁle changes indicating the
changing nature of the pharmacological action.
Fig. 2C depicts one of the ﬁrst projects that beneﬁted from the
SmartCubes system. Different psychostimulant drugs are shown
and compared against Eltoprazine. Despite Eltoprazine being from a
very different class (a partial 5HT1A/1B agonist) it showed similarity
to drugs used in Attention Deﬁcit Hyperactivity Disorder (ADHD).
Using these results and other preclinical experiments that conﬁrmed
activity of this compound in attenuating hyperactivity and
impulsivity in various animal models, PsychoGenics conducted a
proof-of-concept study in adults with ADHD. The study showed both
doses tested (5 mg bid and 10 mg, bid) signiﬁcantly improved ADHD
symptoms using the ADHD rating scale (The Foundation for Medical
Practice Education, www.fmpe.org, 2008) as compared to placebo
(po .003 and .037, respectively).
2.1. Lead optimization
Drug development involves a time consuming lead optimiza-
tion process that depends on laborious and time consuming
structure activity relationship models. Using an in vivo readout
allows fast assessment of alternative modiﬁcations to a pharma-
cophore (Houghten et al., 2008). Fig. 2D shows an example from
Fig. 2. Drug signatures and lead optimization in SmartCubes. A: The signature of an mGlurR2/3 antagonist in SmartCubes showing a strong antidepressant signal at the
class level (the green bar height represents the strength of the antidepressant signal), and a transition from tricyclic to SSRI at the Subclass level. The legend show all classes
some subclasses present in PGI proprietary database. B: Dose-response signature of diazepam in SmartCubes ranging from inactive, to anxiolytic and ﬁnally to sedative
hypnotic as the dose increases. C: Eltoprazine exhibits a mixed signature (green– antidepressant and cyan– psychostimulant) that is similar to other stimulant and non-
stimulant drugs currently used in the treatment of ADHD. D: A lead compound was found combing through available chemical libraries. A desired signature of anxiolytic
(yellow) and psychostimulant signals (cyan) is then sought after by generation of new analogs. Some compounds show a very similar signature (1 and 2) and others show
activity but signatures that deviate from the lead. Compounds 15–17, for example show an antipsychotic signal (purple) and some others are completely inactive (18–19),
despite being chemically similar to the lead. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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one of PsychoGenics' internal drug development programs in
which 1400 compounds were selected from commercially avail-
able libraries. A lead was found based on its interesting signature
in SmartCubes and conﬁrmation of therapeutic effects in standard
tests. As the lead compound had a short half-life a number of
analogs were synthesized and ran through SmartCube. The quick
feedback allowed chemists to quickly proceed through the struc-
ture activity relationship modeling and focus on changes to the
pharmacophore that preserved the desired phenotypic signatures
(Brunner et al., 2012).
Whereas in this project, the mechanism of action was unknown
for much of the development (a phenotypic approach), other
similar projects use target-speciﬁc libraries of known mechanism
of action, even combination of compounds of different mechan-
isms of action in search of speciﬁc synergies.
2.2. Quantitative assessment of a disease phenotype and its
progression
The more than 2000 behavioral features collected from Smart-
Cubes can also be analyzed using machine learning algorithms to
determine the feature set that best represent a disease model and
differentiate it from control.
Feature analysis: de-correlation and ranking. Many of the fea-
tures from SmartCubes are correlated (e.g. rearing counts and
supported rearing counts). Therefore, PsychoGenics forms statis-
tically independent combinations of the original features (further
referred to as de-correlated features) that discriminate between the
two groups more effectively. Each de-correlated feature extracts
information from the whole cluster of the original features, so the
new feature space has lower dimensionality.
Next, PsychoGenics applies a proprietary feature ranking algo-
rithm to score each feature's discrimination power (ability to
separate the two groups, e.g. control and disease). Ranking is an
important part of the analyses because it weighs each feature
change by its relevance: if there is a signiﬁcant change in some
irrelevant feature measured for a particular phenotype, the low
rank of this feature will automatically reduce the effect of such
change in the analyses, so we do not have to resort to the
conventional “feature selection” approach and discard information
buried in the less informative features. The ranking algorithm can
be applied to either the original or the new features to gain insight
about the key control-disease differences.
Feature analysis: quantitative assessment of Disease Phenotype. In
the new feature space, the overlap between the “clouds” (Gaussian
distributions approximating the groups of mice in the ranked de-
correlated features space) serves as a quantitative measure of
separability (“distinguishability”) between the two groups (Fig. 3).
For visualization purposes, we plot each cloud with its semi-axes
equal to the one standard deviation along the corresponding
dimensions.
A third group, “treated”, can be plotted in the same coordinate
system that best discriminates Control and Disease, as shown in
Fig. 3. The drug treatment effect can then be represented as a
combination of two components: one along the direction of the
“recovery line” (the line connecting the centers of the Control and
Disease clouds) shown as a blue arrow, and the component ortho-
gonal to (“pointing away” from) that direction shown as a yellow
arrow. The relative length of the “recovery” (blue) arrow with respect
to the Control-Disease distance can then be interpreted as the
“recovery due to the drug”, whereas the relative length of the “other
effect” (yellow) arrow represents feature changes that move the
Treated group away from the Control group. The summary of this
analysis can be effectively represented as a bar graph (right pane in
Fig. 3) which we typically refer to as the recovery signature.
Fig. 4 shows an example of the ranked features that separate R6/2
mice, a model of Huntington's disease, from its wild type control and
the binary discrimination in a 2D cloud. We ordered the features
according to the rank obtained at each age, and could see very strong
discrimination against the wild type control. However, the features
that were different at 5 weeks of age where different than those
affected at 8 and 12 weeks when pathology starts to be apparent.
Indeed, whereas the signature shows an increasing hypoactive
phenotype at the older ages, it comprised a hyperactive phenotype
at the 5 week mark, possibly signifying a prodromal phase of the
disease.
3. The NeuroCubes system
The NeuroCubes system is a fully automated in-vivo high-through-
put platform that is used to assess motor performance and gait in mice
and rats. The system utilizes computer vision and machine learning
algorithms to automatically track every locomotion detail of an animal
and measure parameters of gait geometry, gait dynamics as well as
non-locomotion behaviors.
Subjects are allowed to freely walk for 5 min in the NeuroCubes
system. Digital videos of the subjects are captured and processed
through computer segmentation algorithms. The resulting ﬁtted
parameters are then analyzed to extract clips of locomotor behavior.
Those clips are further analyzed to extract information about gait
geometry (stride length, step length and base width) and gait
dynamics (stride duration, step duration and swing duration). In
addition, the system provides data relating to the following:
 Average Speed of the animal.
 Paw Image intensity, paw contact area, perimeter of contact
zone, and paw diameter.
 Paw Position relative to the center of the body is registered.
 Body Position as it pertains to movement of the subject.
 Rhythmicity and limb coordination.
The sensitivity of the NeuroCubes system to capture subtle gait
changes allows it to objectively quantify disease progression in
various rodent models of neurodegenerative and neurodevelop-
mental disorders as well as in preclinical models of pain and
injury.
Classiﬁcation algorithms are used to deﬁne and rank the most
dominant features that deﬁne the disease phenotype. Complex
bioinformatics are employed to calculate the discrimination prob-
ability between the control and disease animals which would
help determine onset of the disease phenotype for pharmacological
interventions.
Chronic neuropathic pain remains a widespread disorder within
the health sciences. Lack of translation between preclinical and
clinical research continues to be a challenging problem in this area
as in other neuroscience domains (Brunner et al., 2011; Munafo
et al., 2014; Taneja et al., 2012). Most of the preclinical models of
neuropathic pain that use evoked thermal or mechanical single
endpoints provide poor predictive validity as the majority of human
clinical pain is considered spontaneous in nature. By using the
NeuroCubes system, many behaviors of a freely moving animal are
captured without the need of thermal or mechanical manipulations.
Using sciatic or spinal nerve ligation models the system can deﬁne
the behaviors that best deﬁne symptoms of neuropathic pain by
ranking the features that show discrimination between a sham and
a ligated animal for example. The algorithms can then be applied to
assess the efﬁcacy of therapeutic compounds to reverse these pain
features. It is possible that using this automated, less subjective
approach can provide a better translational tool for neuropathic
pain research.
V. Alexandrov et al. / European Journal of Pharmacology 753 (2015) 127–134130
Fig. 5 shows the effects of acute administration of duloxetine on
paw placement in the chronic constrictive nerve injury model of
neuropathic pain (Bennett and Xie, 1988; Sommer et al. 1997).
Whereas a sham-injured mouse walks on all four paws in a rhythmic
and symmetric way, a nerve injured mouse shows clear avoidance to
place the paw of the ligated side (left hind paw) on the platform
(Fig. 5A and B). Furthermore compensation in gait is seen as the
mouse adds more pressure on the front paws. Following
Fig. 3. Visualization of a binary discrimination in the ranked de-correlated feature space. Left. The two highest ranked de-correlated features form the 2D coordinates plane
for visualization purposes. Mice from the control group are shown as a blue “cloud” and mice from the disease group are plotted in red. From the overlap between the two
clouds we can derive discrimination probability¼1 – overlap, which measures how reliably a classiﬁer can be trained to discriminate between the two groups with zero
corresponding to 100% overlap (and no ability to distinguish the two groups above the chance level) and 100% meaning error free discrimination. Right: The “recovery
signature” graph summarizing the recovery analysis. The overlap (gray) and discrimination probability (red) sum up to 100%. Recovery (blue) ranges from zero up to the
discrimination probability value. “Other behavioral effects” (yellow) represent drug effects in an orthogonal direction. (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 4. Disease signature of the R6/2 mouse model in SmartCube at three different ages showing age-speciﬁc signatures. Features that were increased in the 5 week old mice
are plotted towards the right of the scale (right of the zero value on the x-axis) including mainly measures of increased activity. In the older mice, features are decreased
(towards the left of the zero value on the x-axis), showing the beginning of the hypoactive terminal phase.
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administration of duloxetine, a partial recovery of gait is seen and the
mouse is able to place the injured paw on the platform while
locomoting. These effects are in line with the mechanical allodynia
test showing that duloxetine increases paw withdrawal threshold in
this model (Joshi et al., 2006; Le Cudennec and Castagne, 2014).
Fig. 5C shows quantitative analyses for the effects of duloxetine
on recovering of pain features in both SmartCubes and Neuro-
Cubes systems in the mouse chronic constrictive nerve injury
model and in a standard mechanical allodynia model. The model
mice and sham mice could be differentiated with 87% accuracy in
SmartCubes and 96% accuracy in NeuroCubes. Duloxetine reduced
such separation by 41% and 45% in SmartCubes and NeuroCubes,
respectively.
4. The PhenoCubes system
The PhenoCubes System provides an environment where disease
models or treatments can be assessed over several days. Groups of
mice are challenged in ways that allow the system to detect social,
circadian, motor, and cognitive behaviors, hallmarks of most neurop-
sychiatric disorders. The system acquires a broad range of different
measures that span multiple disease-relevant domains (i.e., cognition,
locomotor activity and circadian patterns), and thus can efﬁciently
capture the complexity of the behavioral phenotype. Complex com-
puter vision and automation eliminate any subjectivity and together
with proprietary data mining algorithms can detect subtle changes
even early in the progression of a disease phenotype. The cognitive
challenges presented in the environment can be employed to identify
compounds with potential to treat cognitive impairment associated
with disorders such as schizophrenia, Alzheimer's disease, and ADHD.
PsychoGenics developed the PhenoCubes through hardware
modiﬁcations of Intellicage units (New Behavior, AG, Zurich, CH)
and addition of custom-built computer vision hardware and soft-
ware. This system enables behavioral phenotyping of group-housed
mice within a home-cage-like environment over multiple days with
minimal experimenter interruption, thereby allowing comprehen-
sive capture of the natural behavioral rhythms of the subjects. A
day/night Camera mounted on top of the cage allows recording of
the subjects and the use of PsychoGenics' proprietary computer
vision software (Fig. 6). Red light is used during the night cycle to
detect the mice while maintaining a low subjective light level.
In Phenocubes mice are tracked with both a micro transponder
and through computer vision, which allows identiﬁcation of individual
mice in group settings. The standard test protocol comprises a condi-
tional discrimination task, although other cognitive tasks can be pro-
Fig. 5. A. Paw image intensity in sham, chronic constrictive nerve injury (CCI) and duloxetine-treated CCI mice. B. Pooled paw position of sham, CCI and duloxetine-treated
CCI mouse. The CCI mouse shows avoidance to place the injured paw on the platform of the NeuroCubes system. Treatment with duloxetine restores this behavior. C. Cloud
graph visualization of the sham, CCI and CCIþduloxetine groups relationships in NeuroCube (left) and the recovery signature graphs in both NeuroCube and SmartCube
(right). The CCI-duloxetine cloud (green) is between the sham and CCI groups suggesting recovery. The quantiﬁcation of this effect shows 41% recovery. Recovery as
measured by SmartCube is similar, at 45%. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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gram using the Intellicage software. Behavioral measures are obtained,
every second for 24 h and for several days, from the Intellicage unit and
from the computer vision software and include measures of explora-
tion, perseverative behavior, cognition, locomotion, rearing, climbing,
social contact and interaction, and other measures.
Models of Huntington's disease are particularly relevant for
demonstration of the utility of this system as they are characterized
by altered cognition, motor activity, and circadian rhythms, all
domains that can all be assessed simultaneously by the Pheno-
Cubes system. As an example, the R6/2 model shows blunted
circadian amplitude in measures of activity as measured by loco-
motion, increased perseverative behavior as measured by repeat
entries to a corner, and reduced rearing and climbing as age and
pathology advance (Balci et al., 2013). PhenoCubes can be used to
track behaviors over 24 h for multiple days at a time and thus can
effectively pick up circadian deﬁcits (Oakeshott et al., 2011),
cognitive and social phenotypes that may be present only during
the dark phase of the light cycle.
PhenoCubes also adds the ability to score social behavior in an
automated way. The system solves visual occlusions by tracking
mice using both computer vision and telemetric data. We used
two wild type strains, the C57 and BTBR strains from Jackson's labs
as an example, as they have very different behavioral patterns.
Phenocube's ability to capture social and activity behavior at the
same time with high temporal precision allows detangling activity
from true social behavior. Our results suggest, for example, that
BTBR mice are not particularly less social than C57 mice, rather the
latter are more active and aggressive (Fig. 6; Kabitzke, Mazzella
and Brunner, Unpublished). Such analyses of social behavior may
prove of great importance for the understanding of social deﬁcits
in animal models of autism and schizophrenia.
5. Future directions
In addition to phenotyping and drug development projects,
PsychoGenics is working on the extension of the systems in two
different directions. The ﬁrst one involves integration of proteomics
and genomics data with the observed behavioral signatures. We are
developing methods to comb though the integrated dataset to ﬁnd
Fig. 6. PhenoCubes system. An inside view of the system showing visual cues and objects for assessment of motor behavior. The circular openings are the entry points and
associated antennae corresponding to the Intellicages system. Two wild type strains that show very different behavioral patterns in many tests were used to assess the
ability of PhenoCubes to measure dyadic social behavior. BTBR mice showed reduced activity throughout days and nights (Mann Whitney, po .002). A simple measure of
casual encounters, crossing of locomotor trajectories, showed a very similar pattern (Mann Whitney, po .002). True active social approaches (approach follow by an
interaction), however, had a different pattern with only a slight non-signiﬁcant trend toward lower approaches in the BTBR mice (Mann Whitney, p4 .18). Other behaviors,
likely of a more aggressive nature, following and chasing, showed again a higher frequency in the C57 mice than in the BTBR (Mann Whitney, po .02). These results are
consistent with the reputation of the C57 as an aggressive strain but somehow inconsistent with lower sociality in the BTBR mice.
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which are the best descriptors for a particular pharmacological or
genetic signature. For example, using a neurodegenerative model,
one can study in a comprehesive way both behavior and gene
expression in the same subjects and then ﬁnd a gene expression
change that best correlates with cognitive deﬁcits. Such gene may
belong to a pathway that has not been investigated before. We hope
that by ﬁnding a best omic predictor of functional deﬁcits, novel
unsuspected targets can be found.
PsychoGenics also developed a way to predict pharmacological
effects of novel, never been tested, compounds through the use of a
comprehensive model that identiﬁes relationships between chemical
features (custom high-resolution chemical ﬁngerprints) and high-
content behavioral readouts: Relationship Preserving Sample Gen-
erator (RPSG). RPSG is able to not only quantify non-linear relation-
ships among all elements of high-content biological readouts and
digitized representations of chemical structures (custom ﬁngerprints),
but also to subsequently generate tractable de-novo virtual chemical
structures with the identiﬁed chemistry–biology relationships. Digi-
tized chemical representation of those virtual compounds with the
corresponding highest scored desired biological response are then
used in the following ways:
 to compare to existing public and private libraries where com-
pounds have been “digitized” the same way, allowing Psycho-
Genics to select the most promising molecules for testing (similar
to Tanimoto similarity scoring except that we assign greater
weights to the more discriminating ﬁngerprint features);
 convert generated ﬁngerprints back to the actual (novel) che-
mical structures using PsychoGenics' proprietary In-Silico
Synthesis engine based on reaction database mining. We found
that 94% of the resulting novel structures produced by RPSG are
tractable (synthesizable).
Recent studies suggest that RPSG-produced hits have very high
probability of showing in vivo activity (490%). Thus, RPSG can be
used to generate virtual libraries for screening (“hit generation”
mode) when the supplied training set of molecules is chemically
diverse (Fig. 7).
In addition, if the training set of molecules is an analog series of
closely related chemical structures, RPSG can be used to optimize
the biological ctivity and/orpotency, which makes it an ideal tool
for lead optimization applications.
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